公开(公告)号：US20220370491A1

公开(公告)日：2022-11-24

申请号：US17760908

申请日：2020-09-16

申请人： National University Corporation Tokyo Medical and Dental University ,  Takeda Pharmaceutical Company Limited

发明人： Takanori Yokota ,  Testuya Nagata ,  Hideki Furukawa ,  Takatoshi Yogo ,  Yasuo Nakagawa ,  Shigekazu Sasaki ,  Ryosuke Tokunoh ,  Tomohiro Seki ,  Kosuke Hidaka ,  Fumiaki Kikuchi ,  Osamu Kubo ,  Takahito Kasahara ,  Takuto Kojima ,  Junsi Wang ,  Norihito Tokunaga

IPC分类号： A61K31/713 ,  A61K47/54 ,  A61P25/00 ,  A61K9/00

摘要： The object of the present invention is to provide a nucleic acid agent that is efficiently delivered to the nervous system, for example, the central nervous system to which drug delivery can be prevented by BBB, and produces an antisense effect on the target transcriptional product at the delivery site, and a composition comprising the same. In an embodiment, the present invention provides a double-stranded nucleic acid complex formed by annealing a first nucleic acid strand that hybridizes to a part of a target transcriptional product and has an antisense effect on the target transcriptional product, and a second nucleic acid strand that comprises a base sequence complementary to the first nucleic acid strand and is bound to a C22-35 alkyl group optionally substituted with a hydroxy group or an analog thereof.

公开(公告)号：US11958845B2

公开(公告)日：2024-04-16

申请号：US17952546

申请日：2022-09-26

申请人： Takeda Pharmaceutical Company Limited

发明人： Masahiro Ito ,  Hideyuki Sugiyama ,  Takeshi Yamamoto ,  Keiko Kakegawa ,  Jinxing Li ,  Junsi Wang ,  Takahito Kasahara ,  Masato Yoshikawa

IPC分类号： C07D413/14 ,  A61P25/28 ,  C07D413/10

CPC分类号： C07D413/14 ,  A61P25/28 ,  C07D413/10

摘要： The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I):




wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US11459325B2

公开(公告)日：2022-10-04

申请号：US16961476

申请日：2019-01-30

申请人： Takeda Pharmaceutical Company Limited

发明人： Yuta Tanaka ,  Tomohiro Ohashi ,  Zenichi Ikeda ,  Yuta Tanaka ,  Florian Pünner ,  Takeshi Yamamoto ,  Keiko Kakegawa ,  Fumiaki Kikuchi ,  Nao Morishita ,  Takahito Kasahara ,  Masaki Seto ,  Minoru Nakamura ,  Kazuaki Takami ,  Masataka Murakami ,  Masaki Daini ,  Satoshi Mikami ,  Minoru Sasaki

IPC分类号： C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00 ,  A61P25/28

摘要： The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US11453661B2

公开(公告)日：2022-09-27

申请号：US17030504

申请日：2020-09-24

申请人： Takeda Pharmaceutical Company Limited

发明人： Masahiro Ito ,  Hideyuki Sugiyama ,  Takeshi Yamamoto ,  Keiko Kakegawa ,  Jinxing Li ,  Junsi Wang ,  Takahito Kasahara ,  Masato Yoshikawa

IPC分类号： C07D413/14 ,  A61P25/28 ,  C07D413/10

摘要： The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.